Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin Addition to Insulin in T2DM
NCT00395343Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Primary completion
- Oct 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin with Placebo (2 arms). Primary endpoint: Change From Baseline in A1C at 24 weeks. Started Dec 2006; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00395343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395343.